Ocular Therapeutix Ownership
| OCUL Stock | USD 9.89 0.17 1.69% |
Shares in Circulation | First Issued 2013-06-30 | Previous Quarter 166 M | Current Value 167 M | Avarage Shares Outstanding 52.7 M | Quarterly Volatility 38.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ocular |
Ocular Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The book value of Ocular Therapeutix was now reported as 0.79. The company recorded a loss per share of 1.29. Ocular Therapeutix had not issued any dividends in recent years. Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Ocular Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 228 people. To find out more about Ocular Therapeutix contact Antony Mattessich at 781 357 4000 or learn more at https://www.ocutx.com.Besides selling stocks to institutional investors, Ocular Therapeutix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ocular Therapeutix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ocular Therapeutix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ocular Therapeutix Quarterly Liabilities And Stockholders Equity |
|
Ocular Therapeutix Insider Trades History
Only 1.0% of Ocular Therapeutix are currently held by insiders. Unlike Ocular Therapeutix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ocular Therapeutix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ocular Therapeutix's insider trades
Ocular Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ocular Therapeutix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocular Therapeutix backward and forwards among themselves. Ocular Therapeutix's institutional investor refers to the entity that pools money to purchase Ocular Therapeutix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-09-30 | 3.5 M | Perceptive Advisors Llc | 2024-09-30 | 3.3 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | Deltec Asset Management Llc | 2024-09-30 | 2.6 M | Octagon Capital Advisors Lp | 2024-09-30 | 2.4 M | Braidwell Lp | 2024-09-30 | 2.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.6 M | Summer Road Llc | 2024-09-30 | 14.4 M | Vr Adviser, Llc | 2024-09-30 | 12.8 M |
Ocular Therapeutix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocular Therapeutix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocular Therapeutix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocular Therapeutix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ocular Therapeutix Outstanding Bonds
Ocular Therapeutix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ocular Therapeutix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ocular bonds can be classified according to their maturity, which is the date when Ocular Therapeutix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Ocular Therapeutix Corporate Filings
F4 | 27th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 4th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.